A5058741495- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Renal Diseases and Glomerulopathies
- Organ Donation and Transplantation
- Central Venous Catheters and Hemodialysis
- Diabetes Treatment and Management
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Renal and Vascular Pathologies
- Pharmaceutical Practices and Patient Outcomes
- Frailty in Older Adults
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Erythropoietin and Anemia Treatment
- Renal Transplantation Outcomes and Treatments
- Healthcare Systems and Reforms
- Potassium and Related Disorders
- Pharmaceutical Economics and Policy
- Bariatric Surgery and Outcomes
- Optimism, Hope, and Well-being
- Nutrition and Health in Aging
- Body Composition Measurement Techniques
- Blood transfusion and management
- Diabetes Management and Research
University of Alberta
2016-2025
Alberta Kidney Disease Network
2012-2017
University of Calgary
2009-2016
University of Ottawa
2009-2012
University of British Columbia
2012
Dalhousie University
2009
University of Manitoba
2007
Frenchay Hospital
1995
Most studies of chronic kidney disease (CKD) and outcomes focus on mortality ESRD, with limited data other adverse outcomes. This study examined the associations among proteinuria, eGFR, cardiovascular (CV) events.
LDL cholesterol (LDL-C) is an important marker of coronary risk in the general population, but its utility people with CKD unclear. We studied 836,060 adults from Alberta Kidney Disease Network at least one measurement fasting LDL-C, estimated GFR (eGFR), and proteinuria between 2002 2009. All participants were free stage 5 cohort entry. followed first eGFR to March 31, 2009; we used validated algorithms applied administrative data ascertain primary outcome (hospitalization for myocardial...
Better understanding of kidney function after living donor nephrectomy and how it differs by characteristics can inform patient selection, counselling, follow-up care. To evaluate this, we conducted a retrospective matched cohort study donors in Alberta, Canada between 2002-2016, using linked healthcare administrative databases. We 604 to 2,414 healthy non-donors from the general population based on age, sex, year entry, urban residence estimated glomerular filtration rate (eGFR) before...
<h3>Background:</h3> Although statins have been shown to reduce the risk of cardiovascular events in patients at low risk, their absolute benefit is small short term, which may adversely affect cost-effectiveness. We sought determine long-term cost-effectiveness (beyond duration clinical trials) low- and high-potency estimate impact on Canada's publicly funded health care system. <h3>Methods:</h3> Using Markov modelling, we performed a cost-utility analysis compared low-potency (fluvastatin,...
Objectives For people with end-stage renal disease requiring haemodialysis, exercise can improve aspects of quality life (QoL). However, the relative benefits and risks different types in this population are unknown. Therefore, pilot study aimed to evaluate feasibility a main evaluating efficacy cycling resistance each performed during haemodialysis treatment on QoL. Methods In factorial (2×2) trial, 31 patients were randomised cycling, resistance, or an attention control. Feasibility was...
As more patients at lower cardiovascular (CV) risk are treated with statins, the balance between benefits and of adverse events becomes increasingly important. We did a population-based cohort study (May 1, 2002 to March 30, 2013) using province-wide laboratory administrative data in Alberta. studied new statin users aged 66 years age older who were not receiving renal replacement therapy baseline. assessed use 30-day intervals allow time-varying assessment exposure Cox proportional hazards...
Polypharmacy is ubiquitous in patients on hemodialysis (HD), and increases risk of adverse events, medication interactions, nonadherence, mortality. Appropriately applied deprescribing can potentially minimize polypharmacy risks. Existing guidelines are unsuitable for nephrology clinicians as they lack specific instructions how to deprescribe which safety parameters monitor.To develop validate algorithms nine classes decrease HD.Questionnaires materials sent electronically.Nephrology...
<h3>Importance</h3> Although the public is aware that cancer associated with excess mortality and adverse outcomes, clinical consequences of chronic kidney disease (CKD) are not well understood. <h3>Objective</h3> To compare incident severe CKD first diagnosis a malignant tumor, focusing on 10 leading causes in men women residing Canada. <h3>Design, Setting, Participants</h3> This population-based cohort study enrolled individuals aged 19 years older or certain types between 2004 2015...
Calcineurin inhibitors (CNI; cyclosporine, tacrolimus) are critical for kidney transplant immunosuppression, but have multiple potential drug interactions, such as with macrolide antibiotics. Macrolide antibiotics (clarithromycin, erythromycin, and azithromycin) often used to treat atypical infections. Clarithromycin erythromycin inhibit CNI metabolism increase the risk of nephrotoxicity, while azithromycin does not.To determine frequency CNI-macrolide co-prescriptions, proportion who...